VolitionRx receives NYSE American non-compliance notice

VolitionRx Limited (NYSE AMERICAN: VNRX) received a notice on February 6, 2026, from NYSE American stating the company does not meet continued listing standards related to stockholders' equity requirements.

The company fails to comply with three sections of the NYSE American Company Guide. Section 1003(a)(i) requires stockholders' equity of at least $2.0 million for companies with losses in two of three recent fiscal years. Section 1003(a)(ii) requires $4.0 million in stockholders' equity for companies with losses in three of four recent fiscal years. Section 1003(a)(iii) requires $6.0 million for companies with losses in five recent fiscal years.

VolitionRx must submit a compliance plan to NYSE American by March 8, 2026, outlining actions to regain compliance by August 6, 2027. If NYSE American accepts the plan, the company will undergo quarterly monitoring. Failure to submit an acceptable plan or achieve compliance by the deadline will trigger delisting proceedings.

The company's common stock continues trading on NYSE American under the symbol "VNRX" but will carry an added ".BC" designation indicating "below compliance" status. The notice does not affect business operations or SEC reporting requirements.

The Henderson, Nevada-based epigenetics company develops blood tests for disease detection and monitoring. VolitionRx operates research facilities in Belgium and maintains offices in the United States and London.

The company stated it intends to submit a compliance plan by the March deadline but provided no assurance it will meet the listing standards within the required timeframe.

You May Also Be Interested In

• Coinbase expands board to ten with appointment of Anthony Armstrong
• NPK International CFO to retire by August 2027, successor search begins
• Anavex regains Nasdaq compliance after filing overdue reports